Beyond Transrectal Biopsy: The Clinical and Economic Case for Robotic-Assisted Transperineal Biopsy

Join your LUGPA peers on this innovation Theater program, Beyond Transrectal Biopsy: The Clinical and Economic Case for Robotic-Assisted Transperineal Biopsy, sponsored by Biobot Surgical U.S. on October 7, 6 PM U.S. Central Time. Listeners will understand the clinical, operational, technological, and financial considerations involved in transitioning from transrectal biopsy to office-based robotic-assisted transperineal prostate biopsy.

The Clinical and Economic Case for Robotic-Assisted Transperineal Biopsy
Wednesday, October 7  •  7 PM - 8 PM EDT 

In this presentation, you will:

• Improve patient safety and experience: Reduce infection risk, antibiotic use, rectal preparation, and concerns associated with the transrectal approach.
• Improve biopsy accuracy and access: Better reach anterior and smaller lesions while maintaining clear needle visualization and reducing prostate deformation during targeting.
• Make transperineal biopsy practical in the office: Robotic assistance provides stable, independent needle guidance, supports procedures under local anesthesia, and reduces manual complexity and staff burden.
• Strengthen practice efficiency and economics: Simplify pre procedure preparation, improve patient turnaround, and take advantage of reimbursement for the primary biopsy and additional lesions.

REGISTER TODAY!

About the speaker:

Jay B. Page, MD

Dr. Page is a fellowship-trained urologist specializing in robotic and minimally invasive surgery. During 13 years of practice in Tucson, Arizona, he established Southern Arizona’s first comprehensive MRI-fusion biopsy program and performed hundreds of robotic and laser procedures for benign and malignant urologic conditions. He also served six years as Chief of Urology and has 10 years of clinical research experience as a principal investigator for novel surgical devices and cancer therapies. He now practices at Summit Urology in Salt Lake City.

Key Learnings:

1. Why practices are moving from transrectal to transperineal biopsy
   Transperineal biopsy may reduce infection risk, eliminate rectal preparation, decrease reliance on antibiotics, and improve patient experience.
2. How transperineal biopsy may improve diagnostic accuracy
   The approach may provide better access to anterior and smaller prostate lesions that can be difficult to sample accurately with transrectal biopsy.
3. Why robotic assistance matters
   Robotic-assisted systems can stabilize and guide the needle independently from the ultrasound probe, reducing the need for a “third hand” and improving needle visualization, targeting, and procedural consistency.
4. How Mona Lisa 2.0 differs from other platforms
   Listeners will understand potential differences involving equipment setup, manual adjustments, magnetic tracking limitations, workflow efficiency, and the ability to document and revisit previously sampled locations.
5. How the procedure can be performed under local anesthesia
   The webcast will explain the transperineal setup and workflow, including how robotic assistance may make office-based procedures under local anesthesia more practical.
6. How the transition may save clinical-team time
   Transperineal biopsy may reduce preprocedure work associated with rectal swabs, antibiotic selection, preparation verification, and infection-prevention protocols.
7. How patient preferences influence adoption
   Patients may increasingly request transperineal biopsy because of concerns about infection, complications, antibiotics, and rectal preparation.
8. How reimbursement may affect practice economics
   Listeners will learn how the proposed reimbursement structure—including payment for the primary procedure and additional lesions—may support adoption in offices and ambulatory surgery centers.
9. How to evaluate whether robotic-assisted transperineal biopsy fits a practice
   Clinicians can consider patient selection, lesion characteristics, staffing, procedure location, workflow, clinical benefits, reimbursement, and financial sustainability

This Innovation Theater webinar is a paid program; LUGPA is not liable for the information presented.
Accuracy of the information presented is the responsibility of the advertiser.